Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
About the study
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Key Inclusion Criteria:
- Meets criteria established in locally applicable Vercise System Direction for Use
- At least 18 years old
EXCLUSION CRITERIA
Key Exclusion Criteria:
* Meets any contraindication in the Vercise System locally applicable Directions for Use
Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Parkinson's Disease
Age
18+
Participants Needed
1500
Est. Completion Date
Dec 31, 2028
Treatment Type
OBSERVATIONAL
Sponsor
Boston Scientific Corporation
ClinicalTrials.gov NCT Identifier
NCT02071134
Study Number
A4010
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?